Neuland Laboratories share news, announcements and annual reports
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Neuland Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1994 on BSE, Oct 2008 on NSE
Last close ₹19,700.00up ₹420.00 (2.18%)BSE ₹19,701.10
Share price at the NSE close on 30 Oct 2026. Previous close ₹19,280.00.
30 Oct: open ₹19,345.00, high ₹19,920.00, low ₹19,025.00
52-week range of traded prices to 30 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹25,275 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 50.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.48
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.17%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 60,08043.6% delivered
Neuland Laboratories orders, deals and press releases
124 filed, newest first. Page 3 of 3.
Jan 2017
Dec 2016
Nov 2016
2 Nov · Business
Oct 2016
Aug 2016
May 2016
Feb 2016
Oct 2015
Aug 2015
May 2015
Dec 2014
Aug 2014
May 2014
Apr 2014
Jan 2014
21 Jan · Business
Board of Directors of the Company on January 21, 2014, had allotted 10,700 fully paid up equity shares of a face value of Rs. 10 each, to eligible employees pursuant to exercise of stock options granted under Employee Stock Option Scheme, 2008. Consequently w.e.f. January 21, 2014, the paid-up equity capital of the Company stands increased to Rs. 7,65,56,780 from Rs. 7,64,49,780.
Oct 2013
Aug 2013
Mar 2013
Feb 2012
Nov 2011
Aug 2011